Sponsored

Jubilant Therapeutics’ differentiated, orally bioavailable molecules address both validated and novel therapeutic targets in oncology and immunology.

Choose your raw materials wisely

Real estate development firm Sterling Bay launches life sciences division starting with Lincoln Yards, a 320,000 square foot site on the Chicago River.

Discover how Eppendorf OEM worked with the market leader in laboratory automation to develop a win-win business model and 25-year partnership.

Discover how Eppendorf OEM worked with the market leader in laboratory automation to develop a win-win business model and 25-year partnership.

When presented with ORLADEYO, both patients and physicians recognized immediately the freedom gained with the once-daily prophylactic therapy and indicated a high willingness to use.

Learn how to unlock product potential in this step-by-step guide to making the most of your commercialization investments.

This is by far the most exciting time in our history as Jubilant Biosys, and certainly the most exciting message Biosys has ever announced simply because of the sheer scale of transformation that we’ve taken on. It’s massive, very achievable, and ultimately truly transformative for us as colleagues, professionals, as an organization, and to our customers.

To support the development of immunodiagnostic assay, Sino Biological has successfully generated biologically active and stable Spike and NP proteins of SARS-CoV-2.

The fourth Amendment of the China Patent Law has been deliberated and was passed on October 17, 2020. It will come into force on June 1, 2021. For the medical industry, China’s proposed patent linkage system can be more favorable to generic drug companies than the U.S. system.